Nifty
Sensex
:
:
18268.40
61350.26
143.00 (0.79%)
383.21 (0.63%)

Pharmaceuticals & Drugs - Global

Rating :
53/99

BSE: 524804 | NSE: AUROPHARMA

703.50
26-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  686.00
  •  705.50
  •  683.40
  •  685.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1717288
  •  11918.36
  •  1063.90
  •  660.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 40,157.30
  • 7.54
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 39,654.13
  • 0.58%
  • 1.77

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 0.60%
  • 9.59%
  • FII
  • DII
  • Others
  • 23.41%
  • 13.82%
  • 0.75%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.27
  • 10.69
  • 8.19

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.25
  • 9.20
  • 6.18

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 18.60
  • 31.66

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.03
  • 15.70
  • 14.66

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.25
  • 3.10
  • 2.59

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.89
  • 10.50
  • 9.84

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
5,701.98
5,924.78
-3.76%
6,001.50
6,158.43
-2.55%
6,364.91
5,895.00
7.97%
6,483.44
5,600.47
15.77%
Expenses
4,492.60
4,667.43
-3.75%
4,726.83
4,842.21
-2.38%
4,996.33
4,686.96
6.60%
5,050.63
4,460.25
13.24%
EBITDA
1,209.38
1,257.35
-3.82%
1,274.67
1,316.22
-3.16%
1,368.58
1,208.04
13.29%
1,432.81
1,140.22
25.66%
EBIDTM
21.21%
21.22%
21.24%
21.37%
21.50%
20.49%
22.10%
20.36%
Other Income
109.90
115.59
-4.92%
78.10
32.59
139.64%
133.40
30.93
331.30%
53.75
20.62
160.67%
Interest
12.88
21.07
-38.87%
18.22
31.83
-42.76%
19.49
37.11
-47.48%
15.71
40.94
-61.63%
Depreciation
279.69
255.52
9.46%
266.00
232.41
14.45%
276.52
250.13
10.55%
257.34
243.31
5.77%
PBT
1,026.71
1,096.35
-6.35%
1,069.24
1,096.82
-2.51%
4,019.86
938.81
328.19%
1,213.51
863.83
40.48%
Tax
247.74
301.19
-17.75%
259.69
214.35
21.15%
1,059.08
232.86
354.81%
387.33
224.37
72.63%
PAT
778.97
795.16
-2.04%
809.55
882.47
-8.26%
2,960.78
705.95
319.40%
826.18
639.46
29.20%
PATM
13.66%
13.42%
13.49%
14.33%
46.52%
11.98%
12.74%
11.42%
EPS
13.14
13.37
-1.72%
13.68
14.75
-7.25%
50.29
12.04
317.69%
13.76
10.92
26.01%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
24,551.83
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
Net Sales Growth
4.13%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
 
Cost Of Goods Sold
9,861.31
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
Gross Profit
14,690.52
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
GP Margin
59.83%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
Total Expenditure
19,266.39
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
Power & Fuel Cost
-
589.28
587.68
556.79
470.95
437.14
419.26
359.60
349.84
324.72
232.36
% Of Sales
-
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
Employee Cost
-
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
% Of Sales
-
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
Manufacturing Exp.
-
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
% Of Sales
-
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
General & Admin Exp.
-
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
130.74
% Of Sales
-
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
Selling & Distn. Exp.
-
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
359.60
305.98
208.20
% Of Sales
-
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
4.44%
5.23%
4.50%
Miscellaneous Exp.
-
576.06
529.75
413.24
298.75
203.97
212.65
227.09
123.20
149.49
208.20
% Of Sales
-
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
1.52%
2.55%
2.42%
EBITDA
5,285.44
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
EBITDA Margin
21.53%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
Other Income
375.15
380.85
191.87
155.32
101.98
115.89
203.80
96.71
21.56
28.54
24.70
Interest
66.30
74.49
305.13
262.60
77.72
66.72
256.70
159.87
310.16
266.64
277.24
Depreciation
1,079.55
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
312.53
248.74
200.53
PBT
7,329.32
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
Tax
1,953.84
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
Tax Rate
26.66%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
PAT
5,375.48
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
PAT before Minority Interest
5,376.60
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
Minority Interest
1.12
1.02
1.45
0.23
0.26
0.47
1.50
4.51
3.78
2.46
0.64
PAT Margin
21.89%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
PAT Growth
77.82%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
-
 
EPS
91.75
92.00
48.82
40.31
41.30
39.20
34.54
26.89
20.02
5.02
-2.11

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
Share Capital
58.59
58.59
58.59
58.59
58.59
58.52
29.20
29.15
29.12
29.11
Total Reserves
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
Non-Current Liabilities
807.17
555.09
358.13
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
Secured Loans
168.40
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
1,084.11
862.08
Unsecured Loans
0.00
0.00
131.07
0.00
3.81
362.71
587.93
178.05
64.15
102.55
Long Term Provisions
157.11
74.71
46.54
55.86
39.13
23.36
24.35
9.18
9.00
4.24
Current Liabilities
10,665.15
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
Trade Payables
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
Other Current Liabilities
2,685.47
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
Short Term Borrowings
4,802.71
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
Short Term Provisions
382.29
511.72
384.67
294.23
261.36
132.93
218.24
126.60
80.09
66.36
Total Liabilities
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
Net Block
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
Gross Block
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
Accumulated Depreciation
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
Non Current Assets
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
Capital Work in Progress
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
Non Current Investment
431.22
554.69
360.20
311.52
245.85
122.94
0.14
19.76
22.24
19.86
Long Term Loans & Adv.
658.44
378.34
396.64
261.91
256.48
236.56
455.27
789.04
237.82
108.12
Other Non Current Assets
53.03
36.61
38.62
86.93
81.29
32.24
30.25
18.40
18.66
0.12
Current Assets
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
Current Investments
159.79
0.02
0.02
0.02
0.02
0.02
19.65
0.03
0.04
18.68
Inventories
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
Sundry Debtors
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
Cash & Bank
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
70.86
Other Current Assets
1,659.59
489.35
1,919.82
1,223.32
1,596.81
831.25
659.57
448.46
407.69
388.98
Short Term Loans & Adv.
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
207.51
216.67
Net Current Assets
9,158.36
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
Total Assets
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
3,328.92
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
PBT
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
Adjustment
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
441.54
387.22
Changes in Working Capital
-1,066.78
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
Cash after chg. in Working capital
4,614.17
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
Net Fixed Assets
-428.04
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
Net Investments
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
Others
3,509.25
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
Cash from Financing Activity
-1,364.81
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
Net Cash Inflow / Outflow
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
136.62
-118.06
Opening Cash & Equivalents
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
183.71
Closing Cash & Equivalent
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73
65.64

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
374.29
287.16
237.08
199.36
159.96
124.50
88.29
64.33
44.74
40.19
ROA
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
ROE
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
ROCE
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
Fixed Asset Turnover
3.73
4.12
4.36
2.44
2.96
2.79
2.55
2.08
1.75
1.71
Receivable days
29.37
29.85
29.56
64.66
89.16
106.53
91.84
93.55
86.28
95.44
Inventory Days
62.82
57.72
59.64
112.70
101.43
100.27
88.91
94.82
105.51
115.91
Payable days
50.82
53.30
58.56
67.77
75.73
81.70
67.49
71.06
57.79
64.70
Cash Conversion Cycle
41.36
34.27
30.63
109.58
114.86
125.10
113.25
117.31
134.00
146.65
Total Debt/Equity
0.23
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
Interest Cover
100.33
13.32
12.76
42.66
46.80
11.69
14.56
5.94
2.40
0.23

News Update:


  • Aurobindo Pharma’s unit recalls 2,820 bottles of Metoprolol tartrate tablets in US market
    4th Oct 2021, 12:23 PM

    Metoprolol tartrate tablets are used to treat high blood pressure

    Read More
  • Aurobindo Pharma’s arm receives USFDA’s approval for Cyclophosphamide Injection
    27th Aug 2021, 09:59 AM

    The product shall be launched in the US market in the near term and will be manufactured in Eugia’s manufacturing facility in India

    Read More
  • Aurobindo Pharma terminates agreement with Cronus Pharma
    21st Aug 2021, 09:41 AM

    The board of Directors in its meeting held on August 20, 2021 has approved the termination of the aforesaid agreements

    Read More
  • Aurobindo Pharma reports marginal fall in Q1 consolidated net profit
    13th Aug 2021, 10:59 AM

    Total income of the company decreased by 3.78% at Rs 5811.88 crore for Q1FY22

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.